Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Venture Life Group Plc LSE:VLG London Ordinary Share GB00BFPM8908 ORD 0.3P
  Price Change % Change Share Price Shares Traded Last Trade
  -1.00 -1.06% 93.00 35,166 11:38:03
Bid Price Offer Price High Price Low Price Open Price
92.00 94.00 94.00 93.00 94.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 18.77 0.71 0.42 221.4 78
Last Trade Time Trade Type Trade Size Trade Price Currency
12:38:37 O 3,227 93.00 GBX

Venture Life (VLG) Latest News

More Venture Life News
Venture Life Investors    Venture Life Takeover Rumours

Venture Life (VLG) Discussions and Chat

Venture Life Forums and Chat

Date Time Title Posts
30/11/202013:18Venture Life Group plc740
25/11/202021:16ValueGrowth Investing35,062
02/4/201509:58Venture Life Group - Intro video-

Add a New Thread

Venture Life (VLG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
12:38:3893.003,2273,001.11O
12:21:1492.351,1111,026.02O
11:55:2892.00245225.40O
11:54:5892.00255234.60O
11:38:0394.0098.46O
View all Venture Life trades in real-time

Venture Life (VLG) Top Chat Posts

DateSubject
02/12/2020
08:20
Venture Life Daily Update: Venture Life Group Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker VLG. The last closing price for Venture Life was 94p.
Venture Life Group Plc has a 4 week average price of 80.50p and a 12 week average price of 80.50p.
The 1 year high share price is 117p while the 1 year low share price is currently 22p.
There are currently 84,026,006 shares in issue and the average daily traded volume is 327,396 shares. The market capitalisation of Venture Life Group Plc is £78,144,185.58.
30/11/2020
11:18
rivaldo: There are some interesting points in Cenkos' long update note from a few days ago: - they've calculated a pro forma forecast for the coming year ssuming the three mooted acquisitions complete reasonably quickly. This produces 6.75p EPS and £11.4m EBITDA, up 62% on the prior forecast - imo that would justify a share price somewhere between 130p-150p - VLG can almost double the manufacturing capacity in Italy from current capacity of 55m units to 100m units for only £7m total investment, with an initial £3m allowing 75m units production - Pharmasource grew 40% in H1'20, and that was before synergies which should deliver further growth in 2021
20/11/2020
15:46
rivaldo: IMO the share price will rise again as investors realise the potential and implications of the likely acquisitions. The Investor's Champion comment seems ridiculously OTT to me. No credit is given for the turnaround in recent times - which was taking root well before COVID - or for the directors' selling being mainly that of the founders, who set up the business a long time ago in 2010. Surely they're allowed to enjoy (admittedly too sizeable imo) fruits of their recent success, whilst retaining significant stakes? As for the "foolish" institutions, this is a dramatic change of tune from Investor's Champion - who only two days ago said about VLG: A reasonably valued healthcare company, there must be a catch"!
20/11/2020
13:28
speedsgh: Well, they've changed their tune since just 2 months ago! (see post 675) On 23rd Sept the CEO said: "...We'll finish the second half of the year in a good net cash position. And that sets us up well for making further acquisitions and we continue to review some good bolt-on acquisitions, and I think the current environment brings good opporunities for that. So we'd expect, using our current resources, NOT REQUIRING AN EQUITY RAISE, to be able to complete some of those and that will add more cash generation and profitability to the bottom line..." [I have highlighted in CAPS] Perhaps the recent share price strength was just too good any opportunity for them to miss.
20/11/2020
13:19
rivaldo: Great move by VLG to raise £34m at this time to take advantage of distressed sellers - and it seems they already have three well advanced potential acquisitions which would cost £25m-£30m and likely be extremely earnings-enhancing, particularly as the products can be produced internally. As co-founders of VLG in 2010 I'm not too bothered about the CEO and Collins selling roughly half their shares into liquidity, and they can't sell any more for at least two years. The 90p price is disappointing overall - but at least us PIs will get the chance to participate for another £2m. I'm pretty sure this fundraising would have been launched a little while ago, which would account (in the traditional way of the City....) for the share price drop to 90p or so. Today's 90p price is the result.
20/11/2020
09:07
rivaldo: Good to see VLG newly tipped on Investors' Champion - subscriber-only though: Https://www.investorschampion.com/channel/blog/a-reasonably-valued-healthcare-company-surely-there-must-be-a-catch "A reasonably valued healthcare company, there must be a catch! (Updated) 18/11/2020 · Venture Life Group PLC (VLG) Many healthcare companies, especially with anything relating to aiding Covid-19, have benefited from a strong share price over the pandemic and it is rare to find something of seemingly reasonable value. The shares received another boost on news that its mouthwash might be effective against COVID-19. Check out our updated research here. Founded in 2010, Venture Life Group (LON:VLG) is an international consumer healthcare company focused on developing and manufacturing non-drug self-care products for the ageing population, which consumers can buy without prescription. The Group's manufacturing is based in Italy, where a 5,500m² factory is being expanded to produce up to 55 million units per annum by the end of the year, producing both Venture Life's own brands as well as products for others as a contract manufacturer. With over 35 years of experience, the site boasts exciting development capabilities thanks to superior laboratory facilities and knowledge of the market. The Group has 10 branded products, covering…"
02/10/2020
12:52
rivaldo: Nice summary from John Rosier in his blog last week, buying more at 101p: Https://johnsinvestmentchronicle.com/venture-life-group-risk-rating-reduced-to-low-added-to-position/ "Venture Life Group: (VLG.L, AIM All-Share: Market Cap £85m, 101p, 6.7% of JIC Portfolio) A reasonable share price response to yesterdays’ results on a poor day for the market. Risk rating reduced to Low. Added to position this morning. Simon Thompson in the Investors Chronicle wrote it up yesterday, pointing to the momentum in the business and the operational gearing that I alluded to yesterday. “When a company with a relatively fixed cost base has the manufacturing capacity to materially increase sales, the impact on margins can be dramatic as a higher proportion of incremental revenue is converted into operating profit.” He also points to the new product launches and not least the launch of Dentyl across 800 of Boots key stores in November. Cenkos has increased forecasts for the full year to £3.3m profits on £30.3m of sales to produce earnings per share of 5.3p rising to 6.0p in 2021. These forecasts exclude any benefit from future earnings enhancing bolt-on acquisitions. Cenkos says it forecasts are “conservative”. I would concur. Simon Thompson has increased his target price to 130p. That looks entirely reasonable to me. Looking back at my notes, the current valuation isn’t much higher than when I first bought in May, due to the big upgrades in earnings forecasts. I think there will be more upgrades during H2 given the momentum and operational gearing in the business. Given net cash on the balance sheet and this momentum, I have today reduced the Risk rating to Low. So Low Risk/High Reward points to a 7.5% position. I have just used the spare cash in the portfolio to take the weighting to 6.7%. I paid 101p for 5439 shares. It is narrowly traded, and I was wary of paying too much!"
11/7/2020
12:29
adamb1978: Hi Homebrew re IDP: your reaction is somewhat similar to my initial reaction to their results, however reflecting on them later in the day I think their EPS this year will come in around 3p-4p. Obviously this year is somewhat anomalous (from memory last year EPS was around 7p-8p) and I'd expect them to be back in excess of 2019 earnings in 2021 however I took the view that for the share price to stay where it is requires the market to look through 2020 earnings. I fear that, despite their balance and the decent slug of director buying in the last 6-9 months, Mr Market might not be prepared to do that and the share price is more likely to hear into the 40s say rather than the 80s. As a result, I took my money off the table and will look for a lower re-entry point. I still thikn they are a good bet given operating leverage to the new products which are coming down the pipe, but that there will be the chance to get back in lower. I had bought in the high 30s in March so have made a decent return, and expect to be back in in the next 6-12 months Adam
11/6/2020
08:19
rivaldo: Nice feature on VLG on Investors' Champion (subscriber-only) - and no, there isn't a catch :o)) Https://www.investorschampion.com/channel/blog/a-reasonably-valued-healthcare-company-surely-there-must-be-a-catch "A reasonably valued healthcare company, there must be a catch! 10/06/2020 · Venture Life Group PLC (VLG) Many healthcare companies, especially with anything relating to aiding Covid-19, have benefited from a strong share price over the pandemic and it is rare to find something of seemingly reasonable value. What is the catch? Founded in 2010, Venture Life Group (LON:VLG) is an international consumer healthcare company focused on developing and manufacturing non-drug self-care products for the ageing population, which consumers can buy without prescription. The Group's manufacturing is based in Italy, where a 5,500m² factory can produce up 130,000 units a day,. producing both its own brands as well as products for others as a contract manufacturer. With over 35 years of experience, the site boasts exciting development capabilities thanks to superior laboratory facilities and knowledge of the market. The Group has 10 branded products, covering 44 global markets and 5 therapeutic areas: Oral Healthcare Proctology Dermatology Neurology Women’s healthcare etc"
23/5/2020
14:05
redartbmud: tlatsatt I don't dispute what you say, and certainly in the early stages of development odf a business it can be a help but the corollary case. 1. Renishaw 52% owned ny McMurtry and Deer. In latter years it has lost vision and drive. This may in part be to size, as it has grown and innovation has become more difficult, Also the growth has led to a size of company that needs a different management approach to build on the culture in a different way. 2. Goodwin. The last LTIP vested with a share issue equivalent to 8% of the shares in issue. Had it reached target that would have been 10% of shares. The vesting price was 10p per share, when the marlet price was c £35 per share. It could be argued that the share price was 'helped' along the way to the target. A major shareholder told me a year before that the share price would definitely hit target, when I thought it impossible. Goodwin also have control of the company. red
20/5/2020
16:49
redartbmud: tlatsatt Extreme volatility isn't too good for my constitution. Big moves, on the back of no news, especially those to the downside, do challenge one's resolve. Rsw is a good case study, the other way. The last set of results were not good, and global market conditions have deteriorated since, as the lockdown took hold. Logic says that their business to supply capital and revenue items to manufacturing industry, that is currently partially closed down or at best operating well below capacity, should result in further deterioration before the situation improves. Based on subdued profitability, the share price ought to be significantly ahead of resukts and forecasts. If that is the case, the sometimes 100p daily share price increase, on an already rising share price, is irrational. red
Venture Life share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
VLG
Venture Li..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201202 13:25:32